CoChat

Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer

The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.

Abstract

Introduction Diabetes mellitus has been linked with adverse prostate cancer (PCa) outcomes. However, role of hyperglycemia in PCa progression is unclear. We evaluated the link between hyperglycemia and PCa survival among Finnish PCa patients. Methods The study cohort included 1770 men with data on fasting glucose and diagnosed with PCa within the Finnish Randomized Study of Screening for PCa in 1995-2009. Additionally, 1398 men had data on glycated hemoglobin (HbA1c). Information on fasting glucose and HbA1c measurements was obtained from the regional laboratory database. Antidiabetic medication use was obtained from the prescription database of the Social Insurance Institution (SII). Time-dependent Cox regression analysis was used to estimate hazard ratios (HRs) and 95% confidence intervals for PCa death among diabetic, impaired glucose tolerant, and normoglycemic men. Results During median follow-up of 9.9 years after the diagnosis, 182 men died from PCa. After adjustment for tumor stage, Gleason grade, and PSA level at diagnosis, diabetic fasting glucose level after PCa diagnosis was associated with elevated risk of PCa death compared to normoglycemic men (HR 1.67 95% CI 1.18-2.36). The risk association was strongest among participants with localized cancer at diagnosis; HR 2.39, 95% CI 1.45-3.93. The risk elevation was observed for glucose measurements taken up to 5 years earlier. Diabetic glucose levels measured before the diagnosis were not associated with PCa death. Co…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41391-018-0123-0

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 26 references

Cited by

See all 13

Metadata

Authors
Murtola, T. J., Sälli, S. M., Talala, K., Taari, K., Tammela, T. L. J., & Auvinen, A.
Affiliations
  • Tampere University (FI)
  • Finnish Cancer Registry (FI)
  • University of Helsinki (FI)
Corresponding author
Murtola, Teemu J.
Venue
Prostate Cancer and Prostatic Diseases
Published
2019-01-24
Volume
22
Issue
3
Pages
453-460
ISSN
  • 1365-7852 (ISSN-L)
  • 1476-5608
OpenAlex
W2914752208
Cited by
13
References
27
Citations by year
2024: 5 · 2022: 3 · 2021: 4 · 2020: 1
FWCI
0.66
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Prostate Cancer and Prostatic Diseases (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
Keywords
prostate cancer, hyperglycemia, fasting blood glucose, HbA1c, diabetes mellitus, impaired glucose tolerance, prostate cancer mortality, disease-specific survival, tumor progression, localized prostate cancer, antidiabetic drugs
MeSH terms
Aged, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Finland, Follow-Up Studies, Glycated Hemoglobin, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Mass Screening, Middle Aged, Neoplasm Staging, Prospective Studies, Prostate, Prostatic Neoplasms, Risk Factors, Survival Analysis, Prostate-Specific Antigen, Disease Progression, Risk Assessment, Neoplasm Grading

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. https://app.cochat.ai/papers/10.1038/s41391-018-0123-0
The paper
Murtola, T. J., Sälli, S. M., Talala, K., Taari, K., Tammela, T. L. J., & Auvinen, A. (2019). Blood glucose, glucose balance, and disease-specific survival after prostate cancer diagnosis in the Finnish Randomized Study of Screening for Prostate Cancer. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-018-0123-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.